COMP <GO>
ELV vs LLY // RETURN ON INVESTED CAPITAL (ROIC)
Elevance Health Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ELV 6
— LLY 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: LLY
LAST: $422.02 (+1.84%) • MKT CAP: $91.18B
roic
8.70%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
roic
32.36%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELV VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELV | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.40% | 83.64% | +5.76 | ELV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 8.70% | 32.36% | -23.66 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.8x | 36.4x | -22.62 | ELV | /valuation <GO> |
| Free Cash Flow Yield | 3.48% | 2.30% | +1.18 | ELV | /fcf-yield <GO> |
| Operating Margin | 3.60% | 40.21% | -36.61 | LLY | /operating-margins <GO> |
| Net Profit Margin | 2.80% | 31.90% | -29.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 12.50% | 45.51% | -33.01 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.68% | 0.49% | +1.19 | ELV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.17 | 9.29 | -6.12 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.0 | 66.6 | -14.60 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.51 | +0.56 | ELV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 13.5x | 26.3x | -12.75 | ELV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $91.18B | $1.29T | -$1.20T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELV REV | LLY REV | ELV GROSS % | LLY GROSS % | ELV FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $199.13B | $65.18B | 89.4% | 83.0% | $3.17B | $16.81B |
| FY 2024 | $177.01B | $45.04B | 88.8% | 81.3% | $4.55B | $8.82B |
| FY 2023 | $171.34B | $34.12B | — | 79.3% | $350.7M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELV // BETA 1.07
LLY // BETA 0.51